HealthLinx Says Sigma-Aldrich Patent Challenge Is Rejected | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Australian biomarker discovery firm HealthLinx said this week that the European Patent Office has rejected Sigma-Aldrich's objection to a patent issued to HealthLinx covering IgY immunodepletion technology.

The patent at the center of the dispute, EP1540304, is entitled, "Depletion of Plasma Proteins," and covers technology that is used in discovering protein biomarkers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.